Symmetry Partners’s Gilead Sciences GILD Stock Holding History

Symmetry Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,041	Closed	-$895K	–	260
2024 Q2	$895K	Buy	13,041 +2,037	+19%	+$136K	0.05%	181
2024 Q1	$806K	Hold	11,004	–	–	0.06%	215
2023 Q4	$893K	Sell	11,004 -10,624	-49%	-$827K	0.05%	178
2023 Q3	$1.62M	Sell	21,628 -1,545	-7%	-$119K	0.09%	109
2023 Q2	$1.79M	Hold	23,173	–	–	0.09%	105
2023 Q1	$1.92M	Hold	23,173	–	–	0.11%	105
2022 Q4	$1.99M	Buy	23,173 +7,161	+45%	+$567K	0.12%	95
2022 Q3	$988K	Sell	16,012 -902	-5%	-$56.9K	0.07%	166
2022 Q2	$1.04M	Buy	16,914 +1,080	+7%	+$66.9K	0.07%	163
2022 Q1	$941K	Buy	15,834 +1,256	+9%	+$80.3K	0.06%	209
2021 Q4	$1.06M	Hold	14,578	–	–	0.07%	195
2021 Q3	$983K	Hold	14,578	–	–	0.06%	224
2021 Q2	$1M	Buy	14,578 +288	+2%	+$19.2K	0.07%	225
2021 Q1	$924K	Sell	14,290 -396	-3%	-$25.5K	0.07%	219
2020 Q4	$856K	Sell	14,686 -500	-3%	-$30.2K	0.07%	221
2020 Q3	$960K	Buy	15,186 +3,058	+25%	+$212K	0.08%	171
2020 Q2	$933K	Buy	+12,128	New	+$929K	0.12%	81

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Symmetry Partners's GILD Position: Q3 2024 in Review

Symmetry Partners sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 13,041 shares — an estimated $895K sold.

Symmetry Partners first reported a position in GILD in Q2 2020 and held it in 17 quarters. The position peaked at $1.99M in Q4 2022. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

Symmetry Partners reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
Symmetry Partners sold 13,041 Gilead Sciences shares in Q3 2024, an estimated $895K.
Symmetry Partners first reported a position in Gilead Sciences in Q2 2020 and held it in 17 quarters.
Symmetry Partners's Gilead Sciences position peaked at $1.99M in Q4 2022.
1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.